PRNewswire/ – BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic protein therapeutics, announced today the U.S. Food and Drug Administration has cleared BioAtla’s Investigational New Drug application for BA3021, a first-in-class conditionally active ROR2-targeted antibody-drug conjugate, in patients with solid tumors.

CAB-ROR2-ADC will be BioAtla’s second CAB investigational product to enter clinical trials in the United States.

Recent studies by others indicate that overexpression of either ROR2 or AXL receptor is associated with resistance to anti-PD-1 therapy thereby suggesting immuno-oncology roles for BioAtla’s first two clinical stage CAB candidates that target these receptors.

BioAtla applies its proprietary CAB technology to develop its CAB antibody-drug conjugate targeting ROR2 with the intent to activate binding to the ROR2 receptor in the tumor microenvironment and deliver the toxic payload only to the cancerous cells.

CAB proteins are designed to deliver their therapeutic payload and/or recruit the immune response in specific and selected locations and conditions within the body and to be active only in the presence of a particular cellular microenvironment.

About BioAtla, LLC BioAtla is a global biotechnology company with operations in San Diego, California.

BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.